S&P 500 Industrials Sector SEC Filings — March 16, 2026

16-03-2026

Forgent Power Solutions reported fiscal Q2 2026 revenues of $296 million, up 69% YoY from $175 million, driven by strong demand in data centers and grid sectors, with bookings surging 268% to $762 million and backlog doubling to $1.5 billion YoY (up 45% QoQ). Adjusted EBITDA increased 51% to $60 million and Adjusted Net Income rose 66% to $36 million, however, the company recorded a net loss of $0.1 million versus a $6.4 million profit in the prior year quarter due to higher SG&A expenses and one-time costs. FY2026 guidance anticipates revenue of $1.275-1.325 billion (73% YoY growth at midpoint), Adjusted EBITDA of $300-310 million, and Adjusted Net Income of $190-200 million.

• ·Cash flow from operations was neutral in Q2 FY2026 due to working capital investment.
• ·Capital expenditures of $26 million primarily for capacity expansion, expected to complete by end of FY2026.
• ·Future maintenance capex expected at approximately 1% of revenues annually post-expansion.
• ·Initial Public Offering priced at $27.00 per share on February 4, 2026, trading under FPS on NYSE from February 5, 2026.
• ·Under-absorbed costs totaled approximately $6 million in Q2 FY2026.

16-03-2026

SAIC reported Q4 FY26 revenues of $1.75B, down 5% YoY from $1.838B, and full FY26 revenues of $7.26B, down 3% YoY from $7.479B, primarily due to contract completions, volume ramp-downs, and government shutdown impacts. While adjusted EBITDA margins improved to 10.3% in Q4 (up 70bps) and 9.7% for FY26 (up 20bps), supported by lower SG&A and other recoveries, Q4 net bookings were weak at $0.6B with a 0.3 book-to-bill ratio. FY27 guidance anticipates revenues of $7.0-7.2B with organic growth of -4% to -2%, adjusted EBITDA of $705-715M, and adjusted diluted EPS of $9.50-9.70.

• ·Q4 net bookings $0.6B with book-to-bill 0.3; FY net bookings $7.8B with book-to-bill 1.1.
• ·FY26 share repurchases $422M (4.0M shares); Q4 repurchases $97M.
• ·Quarterly dividend $0.37/share payable April 24, 2026 to record April 10, 2026.
• ·Notable Q4 awards: $629M from Space and Intelligence Community; $95M GAO TIS contract (5-year).
• ·Post-period awards: $330M Space/IC recompete (7-year); $200M Federal Civilian recompete (5-year).
• ·Weighted-average diluted shares: Q4 45.4M (down from 49.0M); FY 46.5M (down from 50.5M).

16-03-2026

Cypherpunk Technologies reported FY2025 net income of $4.8M, swinging from a $67.8M net loss in FY2024, primarily due to $50.4M unrealized gains on ZEC treasury holdings and sharp R&D expense cuts to $25.7M from $57.2M. The company raised $58.88M via private placement, built ZEC holdings to 294,743 units valued at $147.4M, and invested $5M in ZODL. However, operating loss persisted at $41.1M (improved from $70.1M), cash fell to $14.0M from $47.2M, and restructuring charges hit $4.5M amid headcount reductions.

• ·Appointed Khing Oei as Chairman (Nov 2025), Will McEvoy as CIO/Board (Nov 2025), Zooko Wilcox, Josh Swihart, Arjun Khemani as Strategic Advisors (Dec 2025/Jan 2026).
• ·Private placement issued 15,212,311 common shares, pre-funded warrants for 80,768,504 shares ($0.001 exercise), warrants for 71,985,605 shares ($0.5335 exercise).
• ·Leap Therapeutics advancing sirexatamab registrational pathway discussions with regulators; DKK1-high ORR 44% vs 15.8% control (p=0.0149), mPFS 9.36 mo vs 5.88 mo (HR 0.46, p=0.0168), mOS NR vs 9.66 mo (HR 0.17, p<0.001).
• ·Average ZEC purchase price $335.89.

16-03-2026

Ampco-Pittsburgh reported Q4 2025 net sales of $108.8 million, up 8% YoY from $100.9 million, and full-year sales of $434.2 million, up 4% YoY from $418.3 million, supported by higher shipment volumes in Air and Liquid Processing despite Forged and Cast Engineered Products segment shutdowns. However, Q4 GAAP net loss widened to $57.7 million ($2.85 per share) from prior year due to $54.3 million non-cash after-tax charges for UK cast roll exit and asbestos revaluation, with Adjusted EBITDA declining 47% YoY to $3.2 million; full-year GAAP loss was $66.1 million ($3.28 per share) but Adjusted EBITDA improved 4% YoY to $29.2 million. The UK cast roll facility exit is expected to deliver $7-8 million annual EBITDA uplift as volume shifts to Sweden.

• ·Q4 Adjusted EBITDA bridge: sales volume/pricing +$0.1M, SG&A +$2.3M improvement, but operating overhead absorption -$4.6M and other -$0.6M.
• ·FY Adjusted EBITDA bridge: sales volume/pricing +$6.1M, SG&A +$2.8M improvement, but operating overhead absorption -$7.4M and other -$0.5M.
• ·Conference call scheduled for March 17, 2026 at 10:30 a.m. ET.

16-03-2026

ServisFirst Bancshares, Inc. announced on March 16, 2026, that its Board of Directors declared a quarterly cash dividend of $0.38 per share. The dividend is payable on April 13, 2026, to stockholders of record as of April 1, 2026.

• ·Filing includes Exhibit 99.1: Press Release dated March 16, 2026.

16-03-2026

Marathon Petroleum Corporation filed Definitive Additional Proxy Materials (DEFA14A) on March 16, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific proposals, financial data, or voting matters are detailed in the provided header.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Soliciting Material under §240.14a-12

16-03-2026

WaterBridge reported Q4 2025 produced water handling volumes of 2.6 million barrels per day, up 1% QoQ, and revenue of $208.9 million, up 2% QoQ, while full-year 2025 volumes grew 15% YoY to 2.4 million barrels per day and pro forma revenue increased 19% YoY to $790.0 million with Adjusted EBITDA of $402.8 million (51% margin). However, Q4 net loss widened to $13.6 million (7% margin), gross margin declined to $46.8 million from $58.3 million QoQ, and borrowings increased to $1.465 billion from $609.4 million YoY. The company initiated a $0.05 per share quarterly dividend and guided 2026 Adjusted EBITDA to $420-460 million with 7-9% growth.

• ·Q4 capital expenditures of $89.2M driven by Speedway Pipeline Phase 1 and Stateline expansions.
• ·2026 capex guidance of $430-490M, primarily for Speedway Phases 1/2 and Devon agreement.
• ·2026 volume guidance of 2,500-2,700 thousand barrels per day.
• ·Single-day volume record of 2.9 million barrels per day in Q4 2025.
• ·99.7% operational uptime and <1% measurement variance for FY 2025.
• ·Phase II Speedway expected to add 500,000 bpd capacity in Eddy/Lea counties, NM.
• ·Dividend record date March 5, 2026; payable March 19, 2026.
• ·IPO closed September 18, 2025; Combination assumed January 1, 2024 for pro forma.

16-03-2026

Ferguson Enterprises Inc. (FERG) filed its DEF 14A Proxy Statement on March 16, 2026, for the virtual 2026 Annual Meeting on April 30, 2026, seeking shareholder approval to elect 11 director nominees, ratify Deloitte & Touche LLP as independent auditors for fiscal 2026, and approve on an advisory basis the compensation of Named Executive Officers for the five-month fiscal transition period from August 1 to December 31, 2025. The company highlights its positioning in the $340B residential and non-residential construction markets, strong governance practices, and the successful completion of its fiscal year-end transition to December 31 as of January 1, 2026, aligning with its U.S. headquarters move. No performance declines or flat metrics are disclosed in the filing.

• ·Record date for shareholders entitled to vote: March 3, 2026
• ·Annual meeting details: Virtual webcast at www.virtualshareholdermeeting.com/FERG2026, 4:00 p.m. Eastern Time on April 30, 2026
• ·Fiscal year end transition completed January 1, 2026, from July 31 to December 31

16-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 16, 2026, announcing via attached press release (Exhibit 99.1) the cancellation of a previously proposed increase in authorized shares following a reverse stock split. The disclosure is furnished under Item 8.01 and not deemed 'filed' for liability purposes. The report was signed by CEO Steven Reinharz.

16-03-2026

Urgently reported Q4 2025 revenue of $33.3M, up 4% YoY, gross profit of $8.7M (+23% YoY) with margin expansion to 26% (vs 22%), GAAP operating loss of $2.5M (improved 46% YoY), and non-GAAP operating income of $0.2M. However, full-year 2025 revenue declined 10% YoY to $129.2M despite gross profit growth of 4% and significant operating expense reductions (GAAP -29%, non-GAAP -32%). The company announced a definitive merger agreement to be acquired by Agero, Inc., leading to cancellation of the earnings call and suspension of 2026 guidance.

• ·Q4 consumer satisfaction score of 4.7/5; FY score of 4.6/5.
• ·Cash and equivalents declined to $5.3M as of Dec 31, 2025 from $14.2M prior year.
• ·Total liabilities increased to $90.1M from $85.7M; stockholders' deficit widened to $46.4M from $31.7M.
• ·Q4 net loss of $4.2M improved from $8.7M YoY; FY net loss $20.4M improved from $44.0M.
• ·Revolving credit facility $12.7M as current liability Dec 31, 2025.

16-03-2026

Amphastar Pharmaceuticals, Inc.'s Board of Directors authorized a $50 million increase to the company's share buyback program on March 12, 2026, to primarily offset dilution from equity compensation programs. The program is expected to continue indefinitely, with repurchases potentially made through open market transactions, Rule 10b5-1 plans, privately negotiated deals, or other means in compliance with SEC rules. Timing and volume will depend on factors like share price, regulatory requirements, and market conditions.

• ·Registrant incorporated in Delaware, IRS Employer ID 33-0702205, Nasdaq-listed under AMPH.

16-03-2026

Silvercrest Asset Management Group Inc. (SAMG) issued a press release on March 13, 2026, announcing a teleconference on March 17, 2026, at 8:30 am Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and not deemed filed under securities laws.

• ·Filing submitted on March 16, 2026, covering Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).

16-03-2026

PCB Bancorp reported net income of $37.5M for the year ended December 31, 2025, up 45% YoY from $25.8M in 2024, with net interest income increasing 17% to $104M and total assets growing 7% to $3.28B alongside loans held-for-investment up 7% to $2.82B. Return on average assets improved to 1.15% and efficiency ratio declined to 51.2% from 60.2%. However, nonaccrual loans rose 69% to $7.9M, NPAs increased to 0.24% of assets from 0.15%, provision for credit losses grew 18% to $4.0M, and capital ratios were slightly lower though still well above regulatory thresholds.

• ·Earnings per common share diluted $2.58 for 2025, up from $1.74 in 2024.
• ·Cash dividends declared per common share $0.80 for 2025, up from $0.72.
• ·Dividend payout ratio 30.89% for 2025, improved from 41.14%.
• ·All capital ratios remain well capitalized per PCA thresholds.
• ·ASC 326 adoption increased total ACL on loans by $1.1M to $26.0M.

16-03-2026

Trailblazer Merger Corp I is holding a special stockholder meeting on March 27, 2026, to vote on amending its charter and trust agreement to extend the business combination deadline from March 30, 2026, up to three one-month increments until June 30, 2026, to facilitate its pending merger with Cyabra Strategy Ltd., with sponsor deposits of $0.035 per unredeemed public share per extension. The trust account balance is $4.03M as of March 11, 2026, yielding a $12.11 per share redemption price, while public shares trade at a discount of $10.75. Without approval, the company faces dissolution and liquidation after the current termination date.

• ·Merger agreement originally dated July 22, 2024, and amended November 11, 2024, and November 6, 2025.
• ·Special Meeting via teleconference: US toll-free 877-853-5257 or 888-475-4499; Meeting ID 917-9737-9034; Passcode 619829.

16-03-2026

The 21Shares Dogecoin ETF (TDOG) filed its annual 10-K for the period from inception on September 17, 2025, to September 30, 2025, reporting total assets, net assets, and paid-in capital of $100, with 2 shares issued and outstanding at a net asset value per share of $50.00. No net investment loss, unrealized gains/depreciation, or redemptions occurred during this short inaugural period. However, the filing highlights risks from pseudonymous Dogecoin ownership and potential large-scale sales by substantial holders, which could adversely impact Dogecoin price and ETF shares.

• ·Filing CIK: 0002064314
• ·Entity File Number: 001-43049
• ·Entity Tax ID: 33-7038007
• ·Incorporated in MD
• ·Address: 477 Madison Avenue, 6th Floor, New York, NY 10022
• ·Phone: (646) 370-6016

16-03-2026

Sprott Physical Silver Trust (PSLV) filed its Annual Report on Form 40-F dated March 16, 2026, providing an overview of the Trust's structure, investment and operating restrictions, silver sector context, unit descriptions, net asset value calculation methods, market information, redemption processes, governance, fees, distribution policy, tax considerations, and risk factors. The document includes details on valuation procedures for cash, receivables, liabilities, and portfolio transactions, but contains no specific financial performance metrics, period-over-period comparisons, or quantitative data on assets, income, or changes.

16-03-2026

Sprott Physical Platinum & Palladium Trust (SPPP) filed its 40-F annual report on March 16, 2026, including certification by the principal executive officer affirming that the financial statements fairly present the Trust's financial condition, results of operations, and cash flows for the periods presented. The report provides an overview of the Trust's structure, investment and operating restrictions, platinum and palladium sectors, unit description, NAV calculation methodology, market details, governance, fees, distribution policy, tax considerations, and risk factors. No specific financial metrics, period-over-period comparisons, or performance data are detailed in the provided excerpts.

16-03-2026

Addentax Group Corp. (ATXG) entered into a stock purchase agreement on February 17, 2026, to acquire 34,200,000 shares (62.18% voting control on a fully-diluted basis) of Keemo Fashion Group Limited from Guang Wen Global Group Limited for approximately $5.5M, satisfied via partial transfer of an existing $17.5M bond. The deal is expected to close by May 1, 2026, making ATXG the controlling shareholder of Keemo Fashion, which operates apparel trading in China and a digital publishing platform in Malaysia. This 8-K/A filing amends the original February 19, 2026, 8-K solely to correct a typographical error in the seller's name.

• ·Bond issued August 24, 2023, with one-year tenor (renewable), governed by New York law
• ·Stock Purchase Agreement dated February 17, 2026 (Exhibit 10.1); Bond Transfer Agreement dated February 18, 2026 (Exhibit 10.2)

16-03-2026

Olema Oncology reported Q4 and FY 2025 results with cash, cash equivalents, and marketable securities at $505.4M after generating $218.5M in gross proceeds from a public offering of 11.5M shares, supporting operations through key milestones including OPERA-01 top-line data in fall 2026. The company advanced palazestrant trials (OPERA-01, OPERA-02) and initiated a Phase 1b/2 combo with Pfizer's atirmociclib, while OP-3136 Phase 1 enrollment continues with data in Q2 2026. However, net losses increased to $46.1M in Q4 (up 37% YoY) and $162.5M for FY (up 25% YoY), driven by higher R&D expenses of $43.2M (Q4, +34% YoY) and $157.7M (FY, +27% YoY).

• ·Non-GAAP R&D expenses Q4 2025: $40.6M (vs $27.7M Q4 2024); FY 2025: $145.5M (vs $108.0M FY 2024).
• ·Non-GAAP G&A expenses Q4 2025: $5.2M (vs $2.8M Q4 2024); FY 2025: $15.6M (vs $11.7M FY 2024).
• ·Potential commercial launch preparations for late 2027.
• ·Palazestrant has FDA Fast Track designation for ER+/HER2- mBC post-endocrine + CDK4/6i.

16-03-2026

Public Storage announced on March 16, 2026, the execution of an Agreement and Plan of Merger with National Storage Affiliates Trust (NSA), pursuant to which NSA will merge with Pelican Merger Sub I, LLC (a Public Storage subsidiary), and NSA OP, LP will merge with Pelican Merger Sub II, LLC, becoming a subsidiary of Public Storage Operating Company. A joint press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) were issued and furnished under Item 7.01. The filing includes extensive forward-looking statement cautions and risks related to transaction completion, integration, and shareholder approvals, with no specific financial terms or deal value disclosed.

• ·Filing includes listings of Public Storage's registered securities: Common Shares (PSA), Depositary Shares for Series F through S Preferred Stocks (PSAPrF to PSAPrS), and Guarantees of Senior Notes due 2030 (PSA/30), 2032 (PSA/32), and 2034 (PSA/34).

16-03-2026

Public Storage and National Storage Affiliates Trust (NSA) announced on March 16, 2026, the execution of a Merger Agreement whereby NSA will merge with Pelican Merger Sub I and NSA OP will merge with Pelican Merger Sub II, making NSA a subsidiary of Public Storage. The announcement includes a joint press release (Exhibit 99.1) and investor presentation (Exhibit 99.2). Extensive forward-looking statements highlight risks including failure to obtain approvals, integration challenges, transaction costs, and potential litigation, with no assurance of completion.

• ·Merger structured as NSA merging into Merger Sub I (surviving entity) and NSA OP merging into Merger Sub II (subsidiary of Public Storage Operating Company).
• ·Form S-4 Registration Statement and Proxy Statement/Prospectus to be filed with SEC.
• ·Information under Item 7.01 not deemed 'filed' under Section 18 of Exchange Act.

16-03-2026

Acumen Pharmaceuticals announced a $35.75M private placement of common stock at $3.30 per share, led by RA Capital Management with participation from ADAR1 Capital Management, Sands Capital, and others, expected to close on or about March 16, 2026, to fund the Enhanced Brain Delivery (EBD) program targeting an IND submission in mid-2027. Preclinical data from the EBD program, utilizing JCR Pharmaceuticals' J-Brain Cargo® technology, demonstrated development candidates achieving 14-40x higher brain penetration in non-human primates compared to native antibodies, low anemia risk, and suitability for subcutaneous administration. No negative or flat performance metrics were reported.

• ·Private placement price: $3.30 per share
• ·EBD candidates showed 14-40x higher brain levels in NHPs at 24 hours vs. native antibodies
• ·EBD collaboration with JCR announced in July 2025
• ·Ongoing Phase 2 trial of sabirnetug in early symptomatic Alzheimer’s disease

16-03-2026

Zenas BioPharma reported positive Phase 3 INDIGO trial results for obexelimab in IgG4-RD, achieving a 56% reduction in flare risk and planning BLA submission to FDA in Q2 2026 and MAA to EMA in H2 2026; topline Phase 2 SunStone results in SLE expected Q4 2026. The company secured up to $250M non-dilutive debt from Pharmakon with $75M drawn, bolstering cash to $360.5M and runway into Q2 2027 (potentially Q4 2027 with milestones). However, FY2025 net loss widened to $377.7M from $157.0M YoY due to $171.7M AIPR&D expense and increases in R&D (+29% to $168.1M) and G&A (+79% to $53.3M), despite revenue doubling to $10.0M.

• ·R&D expenses increased $6.5M QoQ to $55.7M in Q4 2025 due to personnel and orelabrutinib costs, offset by lower obexelimab manufacturing.
• ·G&A expenses rose $4.1M QoQ to $15.6M in Q4 2025 from pre-commercialization and public company costs.
• ·AIPR&D of $166.7M in Q4 2025 from $30M cash + $136.7M non-cash equity for InnoCare license (orelabrutinib, ZB021, ZB022).

16-03-2026

Prosperity Bancshares, Inc. issued its DEF 14A proxy statement dated March 16, 2026, for the 2026 Annual Meeting on April 21, 2026, to elect four Class I directors to serve until the 2029 annual meeting, ratify Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026, and hold an advisory 'Say-On-Pay' vote on named executive officer compensation. The record date is March 2, 2026, with 101,489,022 shares of common stock outstanding. The proxy includes sections on director nominees, corporate governance, director and executive compensation, pay versus performance, and audit committee matters.

• ·Annual Meeting location: East Lawn Board Room of Prosperity Bank, 80 Sugar Creek Center Boulevard, Sugar Land, Texas 77478, at 10:00 a.m. local time.
• ·Proxy materials and Form 10-K for fiscal year ended December 31, 2025 available at https://www.proxydocs.com/PB.

16-03-2026

On March 11, 2026, James Peters, Executive Vice President of Whirlpool Corporation, announced his resignation from the company effective March 30, 2026. This follows his previously reported step-down from the roles of Chief Financial Officer and President, Whirlpool Asia, effective December 31, 2025, as part of the company's ongoing talent planning process. No successor has been named in the filing.

• ·Filing signed by Bridget K. Quinn on March 16, 2026
• ·Company directs investors to monitor the 'Investors' section of whirlpoolcorp.com for material disclosures under Regulation FD

16-03-2026

BioMarin Pharmaceutical Inc. announced on March 16, 2026, the discontinuation of dosing and enrollment in Phase 2 CANOPY trials of VOXZOGO for Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency following SCFE events in investigator-sponsored trials. However, no SCFE events have been observed in BioMarin's own Phase 2 trials, hypochondroplasia trials, or in over 5,000 patients treated for achondroplasia with more than 10,000 patient-years of safety data. The Phase 2 CANOPY trials for Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency (95% of ISS enrollees) will continue as planned.

• ·SCFE events observed only in investigator-sponsored trials, not in BioMarin-sponsored Phase 2 trials for the same conditions
• ·Reference to Annual Report on Form 10-K for year ended December 31, 2025

16-03-2026

Baxter International Inc. announced the departure of EVP and CFO Joel Grade to prioritize family matters, with him continuing in an advisory role until April 30, 2026. Anita Zielinski, who joined in 2025 as SVP, Chief Accounting Officer and Controller, has been appointed interim CFO effective immediately while the company searches for a permanent replacement. Baxter is reiterating its full-year 2026 financial outlook originally provided on February 12, 2026, signaling continuity amid the transition.

• ·Anita Zielinski previously served as SVP and CFO, U.S. Foodservice Operations at Sysco Corporation and spent over 20 years at Ernst & Young LLP as an audit partner.
• ·Media Contact: Stacey Eisen, (224) 948-5353; Investor Contact: Kevin Moran, (224) 948-3085

16-03-2026

Waters Corporation disclosed in an 8-K the provision of unaudited condensed combined financial statements, MD&A, and pro forma financial information for Becton, Dickinson and Company's former Biosciences and Diagnostic Solutions business (SpinCo Business), acquired on February 9, 2026, in connection with an anticipated Form S-3 filing. The materials cover SpinCo financials as of December 31, 2025 and September 30, 2025, for the three months ended December 31, 2025 and 2024, fiscal years ended September 30, 2025, 2024, and 2023, and pro forma combined data for Waters and SpinCo as of and for the fiscal year ended December 31, 2025. No performance metrics or period-over-period changes are detailed in the filing body.

• ·SpinCo Business refers to Becton, Dickinson and Company's former Biosciences and Diagnostic Solutions business.
• ·Waters common stock (WAT) trades on the New York Stock Exchange with par value $0.01 per share.

16-03-2026

Associated Banc-Corp filed Definitive Additional Materials (DEFA14A) on March 16, 2026, as part of its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee required and is not preliminary or confidential. No financial metrics, changes, or substantive proxy details are disclosed in the provided notice.

• ·Filed by the Registrant
• ·No fee required

16-03-2026

Orange County Bancorp, Inc. reported net income of $41.6 million for the year ended December 31, 2025, a 49.2% YoY increase from $27.9 million, fueled by net interest income growth of 13.4% to $104.1 million and noninterest income surge of 44.9% to $23.1 million. Average total assets expanded to $2.59 billion from $2.48 billion, with net interest margin improving to 4.18% from 3.83%. However, non-performing loans rose sharply to $11.1 million from $6.3 million, lifting the NPL to total loans ratio to 0.57% from 0.35%, and noninterest expenses increased 4.1% to $67.9 million.

• ·Banking segment net income $37.5M in 2025 vs $25.4M in 2024; Wealth Management $4.1M vs $2.5M.
• ·Provision for credit losses $7.7M in 2025, down 19.4% from $9.6M.
• ·Non-accrual commercial real estate loans $8.7M at Dec 31 2025 vs $6.0M at Dec 31 2024.
• ·Investment securities gains (losses) -$0.6M in 2025.
• ·Proceeds from bank owned life insurance $3.6M in 2025 (new).
• ·Total assets at Dec 31 2025 $2.66B vs $2.51B at Dec 31 2024.

16-03-2026

Babcock & Wilcox Enterprises, Inc. filed an 8-K on March 16, 2026, disclosing under Item 7.01 that it posted an investor presentation on its website (www.babcock.com). The presentation is attached as Exhibit 99.1 and incorporated by reference, but is not deemed 'filed' under securities laws. The filing was signed by Cameron Frymyer, Executive Vice President and Chief Financial Officer.

• ·Commission File Number: 001-36876
• ·IRS Employer Identification No.: 47-2783641
• ·Principal Executive Offices: 1200 East Market Street, Suite 650, Akron, Ohio 44305
• ·Telephone: (330) 753-4511

16-03-2026

Embassy Bancorp, Inc. reported total assets of $1.80B as of Dec 31, 2025, up 5.6% YoY from $1.70B, driven by loan growth to $1.28B net (up 1.8%) and deposits to $1.64B (up 5.6%), with net interest income rising 17.2% YoY to $42.4M and net interest margin expanding to 2.52% from 2.26%. Stockholders' equity increased 19.9% to $127.6M, supported by retained earnings growth and reduced accumulated other comprehensive loss. However, nonperforming loans remained flat at 0.04% of total loans, and certain yields like interest-bearing deposits declined to 4.28% from 5.32%.

• ·Average taxable loans: $1.25B in 2025 (up from $1.24B), interest $57.3M (up 7.3%).
• ·Securities available for sale: $342M at Dec 31, 2025 (up from $281M).
• ·Allowance for credit losses: $12.0M at Dec 31, 2025 (down slightly from $12.2M).
• ·Net charge-offs to average loans: 0.01% in 2025 (vs -0.02% recovery in 2024).

16-03-2026

Lexicon Pharmaceuticals, Inc. (LXRX) filed Definitive Additional Proxy Materials (DEFA14A) on March 16, 2026, pursuant to the Securities Exchange Act of 1934. The filing appears related to a proxy notice for an event dated April 22, 2026, with no specific proposals, financial metrics, or performance data disclosed in the provided content. Company details include fiscal year end December 31, incorporation in Delaware, and headquarters in The Woodlands, TX.

• ·CIK: 0001062822
• ·EIN: 760474169
• ·SIC: Pharmaceutical Preparations [2834]
• ·Business Address: 2445 Technology Forest Blvd., Suite 1100, The Woodlands, TX 77381
• ·Phone: 281-863-3000
• ·Former Names: LEXICON PHARMACEUTICALS, INC./DE (changed 2007-04-26), LEXICON GENETICS INC/TX (changed 2000-01-26)
• ·SEC File Number: 000-30111

16-03-2026

Phreesia, Inc. refinanced its $110 million bridge loan—originally used for the AccessOne Acquisition—with a new $275 million senior secured revolving credit facility from Capital One, borrowing $92.2 million at closing to repay the remaining balance after a $20 million repayment during the fiscal quarter ended January 31, 2026. The new facility replaces a prior $50 million asset-based revolver and is expected to reduce borrowing costs while enhancing financial flexibility, according to CEO Chaim Indig. No penalties were incurred in terminating the bridge loan or prior facility.

• ·Bridge loan was a 364-day $110M secured term loan dated November 12, 2025.
• ·Phreesia founded in 2005.
• ·New Credit Facility available for working capital, capital expenditures, permitted acquisitions, and general corporate purposes.

16-03-2026

InnoCan Pharma Corp, a pre-clinical stage company, filed an F-1 registration statement on March 16, 2026, for an IPO offering 3,750,000 units (or pre-funded units) at an assumed midpoint price of $5.50 per unit, expecting approximately $17.98M in net proceeds ($20.82M if over-allotment exercised), primarily for LPT-CBD R&D ($11.68M human, $4.49M veterinary), marketing ($1.80M), and working capital. Revenues surged 115% YoY to $29.4M in 2024 from $13.7M in 2023, with operating loss improving to $1.2M from $3.8M and net loss narrowing to $0.26M from $4.2M; however, nine-month revenues declined 10% YoY to $21.6M in 2025 from $24.0M in 2024, with operating loss remaining flat around $0.3M. Post-offering, common shares outstanding will increase to 8.25M (or 8.81M if over-allotment), following a 65-for-1 reverse split on September 5, 2025, amid an accumulated deficit of $38M.

• ·Reverse share split completed September 5, 2025, at 65-for-1 ratio.
• ·Warrants exercisable at $6.875 per share (125% of $5.50 public offering price), expire in 5 years.
• ·Pre-funded warrants exercisable at $0.001 per share.
• ·Lock-up: Directors/executive officers 180 days, 5%+ holders 90 days from closing.
• ·Excludes 232,666 options (avg $15.90), 442,149 reserved options, 736,420 warrants (CAD$11.05-$50.05), 127,391 convertible debenture (CAD$9.75), 354,615 RSUs from post-offering share count.
• ·Proposed NYSE American symbols: INNP (common shares), INNPW (warrants); other exchanges: INNO (CSE), INNPD (OTCQB), IP4 (Frankfurt).

16-03-2026

Gevo, Inc. disclosed that Dr. Angelo Amorelli informed the Board on March 11, 2026, that he will not stand for re-election at the 2026 Annual Meeting of Stockholders for personal reasons, with no disagreements on operations, policies, or practices. He will continue serving until the expiration of his term at the Annual Meeting. The company expressed thanks for his contributions.

• ·Filing date: March 16, 2026
• ·Date of earliest event: March 11, 2026

16-03-2026

Cue Biopharma, Inc. issued its definitive proxy statement for the 2026 Annual Meeting on April 13, 2026, proposing the election of seven director nominees (Usman Azam, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, Jill Broadfoot, and Pasha Sarraf), ratification of RSM US LLP as independent auditors for the fiscal year ending December 31, 2026, advisory approval of named executive officer compensation, and an amendment to effect a reverse stock split at a ratio between 1-for-30 and 1-for-50 at board discretion. The meeting will be held virtually with a record date of March 9, 2026. No period-over-period financial metrics or performance changes are disclosed in the provided filing content.

• ·Record date: March 9, 2026.
• ·Annual Meeting: April 13, 2026, 9:00 a.m. ET, virtual at www.virtualshareholdermeeting.com/CUE2026.
• ·Proxy materials available/mailing date: on or about March 16, 2026.
• ·References 2025 Annual Report on Form 10-K for fiscal year ended December 31, 2025.

16-03-2026

IPG Photonics Corporation announced via press release that the Local Division of the Unified Patent Court in Dusseldorf, Germany, issued a decision on March 16, 2026, in a previously disclosed patent infringement lawsuit brought by affiliates of Trumpf SE & Co. KG against IPG Laser GmbH & Co. KG, the Company's German subsidiary. The press release is attached as Exhibit 99.1. No financial impact or specific details on the decision outcome were disclosed in the filing.

16-03-2026

Liberty Broadband Corporation's board of directors declared a quarterly cash dividend on its Series A Cumulative Redeemable Preferred Stock, payable on April 15, 2026, to stockholders of record as of March 31, 2026. The announcement was issued via press release on March 12, 2026, under Regulation FD disclosure. No other financial metrics or performance comparisons were provided.

• ·SEC filing dated March 16, 2026, for event on March 12, 2026
• ·Company headquartered at 12300 Liberty Blvd., Englewood, Colorado 80112

16-03-2026

Comtech reported Q2 FY26 net sales of $106.8 million, down 15.6% YoY from $126.6 million, primarily due to strategic elimination of low-margin products and U.S. government shutdown impacts, with S&S segment sales declining 31.3% to $50.6 million. However, gross profit rose to $36.2 million (33.9% margin vs. 26.7% prior), Adjusted EBITDA increased 214% to $9.1 million, operating loss narrowed to $1.2 million from $10.3 million, net bookings surged 120.9% to $175.4 million (1.64x book-to-bill), and backlog reached $731.6 million. Allerium segment sales grew 6.2% YoY to $56.2 million, while the company generated $4.9 million in operating cash flow and ended with $49.9 million liquidity.

• ·S&S book-to-bill ratio improved slightly to 0.68x from 0.64x YoY.
• ·Allerium book-to-bill ratio 2.51x vs. 0.61x YoY.
• ·Backlog decreased to $731.6M from $763.8M YoY but up from $672.1M prior quarter.
• ·Ongoing litigation with former CEO Ken Peterman via American Arbitration Association.